Evaluating the Impact of Cash Transfers on Tuberculosis (TB) Care: ExaCT TB Study

Phase 4

Recruiting

• Conditions: Tuberculosis

• Registration Number: PACTR201906852160014
• Lead Sponsor: niversity of California San Francisco

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-04-05
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 6500

Inclusion Criteria

1. (Site-level) Use standard (multi-day) sputum smear microscopy and/or GeneXpert testing as the primary method of TB diagnosis
2. (Patient-level): Aged =18 years
3. (Patient-level): Initiate evaluation for active pulmonary TB at a community health center (HC IV) enrolled in the study
4. (Provider-level): All providers (e.g., physicians, nurse practitioners, midwives, laboratory staff) (a) aged =18 years; (b) employed by the community health center (HC IV); and (c) involved in the conduct or supervision of health center work related to diagnosis and management of TB

Exclusion Criteria

1. (Site-level) Do not agree to participation
2. (Site-level) Perform sputum smear examination on <150 patients per year (based on 2015 data)
3. (Site-level) Diagnose <15 smear-positive TB cases per year (based on 2015 data)
4. (Site-level) Have on-going economic support program(s) for patients
5. (Patient-level) Have sputum collected for monitoring of response to anti-TB therapy
6. (Patient-level) Have sputum collected as part of active, community-based case finding (e.g., contact tracing, community outreach campaign)
7. (Patient-level) Referred to a study health center for TB treatment after a diagnosis is established elsewhere
8. (Patient-level) Started on TB treatment for extra-pulmonary TB only

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion treated for microbiologically-confirmed TB within two weeks of initial submission of sample for sputum-based testing<br>;Number initiating treatment for microbiologically-confirmed TB within two weeks of submission of sample for sputum-based testing